Shree Pacetronix Ltd. has successfully completed the conversion of 75,150 warrants into equity shares, following board approval on March 20, 2026. The conversion represents a significant capital restructuring exercise that strengthens the company's equity base while providing additional funds for business operations.

Warrant Conversion Details

The board of directors approved the allotment of 75,150 equity shares pursuant to the conversion of an equal number of warrants held by promoter Akash Sethi. The conversion was executed at a predetermined issue price structure that reflects the company's current valuation.

Shareholding Impact

The warrant conversion has resulted in changes to the promoter's shareholding pattern and the company's overall capital structure. Akash Sethi's equity participation has increased substantially while maintaining a significant warrant position for potential future conversions.

Capital Structure Enhancement

Following the successful conversion, Shree Pacetronix's paid-up equity share capital has increased substantially. The company now maintains a stronger equity foundation that supports its long-term growth objectives and operational requirements.

Regulatory Compliance and Filing

The warrant conversion process was conducted in full compliance with SEBI regulations, including the Listing Obligations and Disclosure Requirements and the Issue of Capital and Disclosure Requirements Regulations, 2018. The company has fulfilled all disclosure obligations and maintained transparency throughout the conversion process.

The conversion follows the company's earlier warrant allotment communication dated November 14, 2025, demonstrating the systematic execution of the capital raising plan. The board meeting was held from 05:30 P.M. to 06:15 P.M., with all procedural requirements met, including the receipt of the balance 75% payment from the warrant holder. The intimation has been filed with BSE Limited under scrip code 527005 and hosted on the company's website at www.pacetronix.com , ensuring complete regulatory compliance and transparency.

Biofil Chemicals and Pharmaceuticals Ltd has announced its unaudited financial results for the third quarter ended December 31, 2025, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were digitally signed and released on February 14, 2026.

Financial Performance Overview

The company's financial performance for Q3 FY26 showed mixed results compared to the previous year. The detailed financial metrics demonstrate the company's operational performance during the quarter.

Key Financial Metrics

The company maintained its equity share capital at Rs. 1627.38 lakhs across all reported periods. Earnings per share metrics for the quarter showed consistent performance between basic and diluted calculations.

Regulatory Compliance and Disclosure

The financial results were prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 as amended. The complete format of the unaudited financial results has been filed with stock exchanges and is available on the company's website at www.biofilgroup.net , as well as on BSE ( www.bseindia.com ) and NSE ( www.nseindia.com ) websites.

Company Information

Biofil Chemicals and Pharmaceuticals Ltd operates under CIN: L24233MP1985PLC002709 with its registered office located at B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.) India. The results were signed by Ketan Shah, Chairman & Managing Director (DIN: 08818212), and released from Indore on February 13, 2026.

The company has also provided a Quick Response (QR) code for easy access to the detailed financial results, enabling stakeholders to quickly retrieve comprehensive financial information.

Source: